transmembrane protein 107Genealiases: GRVS638 · JBTS29 · MKS13 · PRO1268
Q-omics provides the consensus-scored TMEM107 profile across patient tissues and cancer cell-line models. TMEM107 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TMEM107 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TMEM107 RNA expression shows 18,790 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, KICH, and KIRP as cancer lineages where TMEM107 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM107 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM107 survival associations across molecular data types. TMEM107 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM107 RNA expression–survival associations across cancer types. High TMEM107 expression shows unfavorable associations in LGG, CHOL and LIHC, but favorable associations in UCEC, KIRP and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TMEM107 RNA expression.
This table summarizes TMEM107 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM107. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM107 shows lower tumor expression in KICH and higher tumor expression in BLCA, LIHC, COAD, HNSC and CHOL. The KICH box plot shows higher TMEM107 RNA expression in normal versus tumor tissue (log2 FC = −1.941, t-test p < 0.001).
This table shows molecular features associated with TMEM107 in patient tissues and cancer cell lines. In patient samples, TMEM107 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM107 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
